enzastaurin + gemcitabine

**Enzastaurin + gemcitabine** is a combination regimen composed of **enzastaurin**, an oral small molecule inhibitor of serine/threonine kinases, and **gemcitabine**, a nucleoside analog chemotherapy. Enzastaurin primarily targets the **protein kinase C beta** (PKC-β) and **phosphatidylinositol 3-kinase/AKT** pathways, leading to inhibition of tumor angiogenesis, proliferation, migration, and induction of apoptosis[2][3]. Gemcitabine is a cytotoxic agent that impedes DNA synthesis through incorporation into DNA and inhibition of ribonucleotide reductase. This combination has been studied in advanced cancers, including transitional cell carcinoma, with evidence of synergistic antitumor activity in preclinical and early-phase studies[3]. The regimen is characterized as targeted antineoplastic therapy plus conventional cytotoxic chemotherapy.